The expected decline in total revenue might initially concern investors, but the projection of stable core pharmaceutical revenue and an increase in operating income and margin expansion could offset negative sentiment. The mixed outlook suggests a neutral short-term impact on Biogen's stock price, as the positive aspects of the forecast may balance out the negative revenue growth expectation.